Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
about
Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectThe clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Lenalidomide enhances anti-myeloma cellular immunityNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioClinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaAutologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialCombination immune therapies to enhance anti-tumor responses by NK cells.Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplCost-effectiveness of lenalidomide in multiple myeloma.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Immune maintenance of self in morphostasis of distinct tissues, tumour growth and regenerative medicine.Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Continuous treatment in multiple myeloma - ready for prime time?Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.The role of natural killer cells in immunity against multiple myeloma.Evolving therapeutic paradigms for multiple myeloma: back to the future.Can we change the disease biology of multiple myeloma?Novel immune modulators used in hematology: impact on NK cellsImmunotherapy for multiple myeloma.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityProgress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective.Targeting the bone marrow microenvironment in multiple myeloma.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Targeting the Bone Marrow Microenvironment.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionModulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression.Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.Role of allogeneic transplantation in multiple myeloma in the era of new drugs.Monitoring NK cell activity in patients with hematological malignancies.Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
P2860
Q26751011-F037DE13-EAAA-471A-A396-31653C5443BEQ26771331-678B0DFC-E132-4BD0-A005-6E80EF664012Q26826830-C98A0785-F382-4078-94A1-39E8CDA71C5CQ33398044-36737CFE-0E9D-462A-8ACB-98478B2C3B67Q33405278-BFE44B39-DF12-4AF4-AB10-60D2E88C9F42Q33903133-48359BF5-38CB-4767-A00D-28685FC70F68Q34202277-94E3B20D-31F0-4E94-86AD-067AFEA60584Q36252792-992EDE94-2080-4EEC-B7DC-C3936F847911Q36414249-BC32FAD2-B993-49A2-9C82-8EC5D0ED9C85Q36725446-EA96B033-7552-48C7-8E9A-CD5C0D9ED0EFQ37408550-A1596AE9-EFCA-47BB-A60D-3A8ED60B5D56Q37609957-491E05E3-EDCF-4A70-8C97-923BA0567634Q37764870-48080623-3D01-4F0C-BB09-D6250CD48609Q37822742-E90EB207-8091-4859-8AC2-2C112066B628Q37825924-1F4F665F-4C29-40ED-A2EF-11EE26AAF855Q37832506-C4B266D3-69F3-4410-A87A-1140B790413AQ37936111-56B90D07-F145-4644-8703-2E5683EA95A6Q37991783-5C446DCD-633E-4E71-B573-277D78E4E968Q37994234-9ACF4354-8FDD-4B5A-88D8-8F2BE92AFA47Q38033590-2194A1A9-A438-4DB2-AF3F-AC46DC197B12Q38062038-58122257-86F4-4F3A-B8FC-5DCFFE72C4D6Q38073760-F3752EBC-2261-4313-9117-B4222C83387DQ38177879-CFDE5EB8-48B3-417E-99F3-5F21289A79DDQ38203261-B49D4C67-48BF-4E90-A93C-E9C69A53D7A4Q38285256-EC38172D-E4B5-487C-976C-D6A2D6F9C15EQ38289041-6C4E6D0C-B50B-4119-9C97-0F2D023741C5Q38417073-577F5EAC-B5DE-4295-89EA-8005EA660AA0Q38708402-FDF0509E-F28A-4134-BB43-C5C9E7A881B0Q38970585-5C182CA5-3BB2-43ED-B673-2BF906F8E6A9Q39136762-A1BA0170-9E0B-4D8B-8483-6D8FDCAF6ABCQ39168624-F46AC8ED-D0E5-44C7-B09D-F0C3ADF77709Q39341524-3D257F90-C53C-4829-B78B-DD48AA51A465Q39933810-667E879E-CD0F-4559-97FB-4BBD3D8977ECQ41826765-DD0BA41F-AEA0-450C-966E-502AEE2EA4A4Q42323676-6A7F33C2-5583-4802-AB17-515C13D55300Q42588915-A3453B21-E562-44A0-82BE-7D55346F1D2FQ42847576-7BD09E3B-C77D-4BCC-8791-38D2712CB6EBQ44314310-91AAE106-230D-493F-9EDD-118CF136869FQ44788740-8A33E6B5-F166-4271-A915-E385044C1927Q48193682-44339AB3-B316-4894-B078-6E8C73E868A6
P2860
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@ast
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@en
type
label
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@ast
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@en
prefLabel
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@ast
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@en
P2093
P2860
P356
P1476
Lenalidomide as salvage therap ...... 4(+)) and T (HLA-DR(+)) cells.
@en
P2093
A Badbaran
A R Zander
C Wolschke
D Atanackovic
F Hoffmann
G Schilling
J El-Cheikh
P2860
P2888
P304
P356
10.1038/BMT.2009.155
P407
P50
P577
2009-07-06T00:00:00Z
P5875
P6179
1018363617